Whitegate Investment Counselors’s Moleculin Biotech MBRX Stock Holding History

Whitegate Investment Counselors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-45	Closed	-$62K	–	230
2021 Q2	$62K	Hold	45	–	–	0.01%	220
2021 Q1	$69K	Hold	45	–	–	0.01%	210
2020 Q4	$81K	Hold	45	–	–	0.01%	206
2020 Q3	$83K	Hold	45	–	–	0.02%	193
2020 Q2	$99K	Hold	45	–	–	0.02%	189
2020 Q1	$62K	Hold	45	–	–	0.02%	175
2019 Q4	$93K	Sell	45 -22	-33%	-$51.5K	0.02%	198
2019 Q3	$168K	Hold	67	–	–	0.03%	190
2019 Q2	$190K	Hold	67	–	–	0.04%	189
2019 Q1	$123K	Buy	67 +13	+24%	+$38.7K	0.03%	188
2018 Q4	$127K	Buy	54 +11	+26%	+$31.6K	0.03%	183
2018 Q3	$155K	Hold	43	–	–	0.03%	162
2018 Q2	$174K	Hold	43	–	–	0.04%	183
2018 Q1	$175K	Buy	+43	New	+$186K	0.04%	183

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

OQS

Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Whitegate Investment Counselors's MBRX Position: Q3 2021 in Review

Whitegate Investment Counselors sold out of Moleculin Biotech (MBRX) in Q3 2021, closing a stake of 45 shares — an estimated $62K sold.

Whitegate Investment Counselors first reported a position in MBRX in Q1 2018 and held it in 14 quarters. The position peaked at $190K in Q2 2019. 21 funds tracked by Wall St. Rank hold MBRX as of Q3 2021.

Whitegate Investment Counselors reported no remaining Moleculin Biotech position as of Q3 2021 after selling out during the quarter.
Whitegate Investment Counselors sold 45 Moleculin Biotech shares in Q3 2021, an estimated $62K.
Whitegate Investment Counselors first reported a position in Moleculin Biotech in Q1 2018 and held it in 14 quarters.
Whitegate Investment Counselors's Moleculin Biotech position peaked at $190K in Q2 2019.
21 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2021.

Based on Whitegate Investment Counselors's 13F filing for Q3 2021, filed 15 Oct 2021.